Arbutus生物製藥 ABUS 深 滬
等待開盤 12-23 09:30:00 美东时间
4.72
+0.290
+6.55%
華盛通- 最 高4.75
- 今 開4.46
- 成交量 63.04万股
- 最 低 4.45
- 昨 收 4.43
- 總市值 9.06亿
- 52周最高 5.10
- 市盈率 靜 --
- 換手率 0.33%
- 52周最低 2.705
- 委 比 62.58%
- 總股本 1.92亿
- 歷史最高 31.48
- 量 比 0.51
- 振 幅 6.77%
- 歷史最低 0.821
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arbutus Biopharma CEO Discusses Lawsuits Over LNP Technology
Arbutus Biopharma ( ($ABUS) ) has issued an announcement. On December 11, 2025,...
12-11 21:29
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
11-15 04:56
Arbutus Biopharma Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $529.000K Miss $1.267M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 60 percent increase over losses of $(0.10) per share from
11-13 20:31
乳腺癌现“年轻化”趋势 早筛早诊早治是关键
（来源：经济参考报） 近日，GE医疗与铿锵玫瑰战友团（乳腺癌公益爱心组织）联合举办了“炽热之爱 与光同尘——玫瑰绽放”公益艺术展，向社会积极传递“早筛、早诊...
10-22 04:00
乳腺癌：从“健康杀手”到“可管可控”的慢性病
转自：中国科学报 “乳腺癌可防、可治、可控，关键在于早筛、早诊、早治。”近日，在GE医疗与铿锵玫瑰战友团（乳腺癌公益爱心组织）联合主办的“炽热之爱 与光同尘—...
10-20 16:08
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Arbutus Biopharma announced that four abstracts, including imdusiran and AB-101 data, were accepted for poster presentations at AASLD 2025. Notably, the AB-101 abstract was selected as a Poster of Distinction. The studies highlight imdusiran's safety, tolerability, and potential to enhance immune responses in chronic hepatitis B patients, while AB-101 showed promising safety and efficacy as a PD-L1 inhibitor. These findings underscore progress to...
10-07 12:00
Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit
The latest update is out from Arbutus Biopharma ( ($ABUS) ). On September 9, 20...
09-10 21:30
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
08-11 19:22
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences announced positive interim results from a Phase 1b study of ABI-5366, a long-acting HSV helicase-primase inhibitor, in participants with recurrent genital herpes. The 350 mg weekly oral dose showed 94% reduction in HSV-2 shedding rate, 98% reduction in high viral load shedding rate, and 94% reduction in genital lesion rate compared to placebo, all statistically significant. The drug demonstrated favorable safety and tolerabil...
08-08 12:00
